Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Neoplasms 2Breast Neoplasms 2Wounds and Injuries 1Stroke 1Stomach Neoplasms 1Spinal Cord Injuries 1Rectal Neoplasms 1Pain, Postoperative 1Muscular Atrophy 1Muscle Spasticity 1Low Anterior Resection Syndrome 1Hereditary leiomyomatosis and renal cell cancer 1Ganglion Cysts 1Esophageal Neoplasms 1Cluster Headache 1Carcinoma, Renal Cell 1Breast Diseases 1Brain Injuries 1

Interventions

Cisplatin 90Fluorouracil 76Radiotherapy 63Paclitaxel 58Docetaxel 49Oxaliplatin 48Irinotecan 42Leucovorin 32Capecitabine 31Carboplatin 27Radiation 21Surgical Procedures, Operative 20Esophagectomy 20pembrolizumab 15Neoadjuvant Therapy 15Bevacizumab 15Cetuximab 13Drug Therapy 12Epirubicin 11Chemotherapy, Adjuvant 9S 1 (combination) 8Magnetic Resonance Spectroscopy 8Gemcitabine 8Trastuzumab 7Nivolumab 7Erlotinib Hydrochloride 7Surveys and Questionnaires 6Panitumumab 6Immunohistochemistry 6Chemoradiotherapy 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Esophageal Neoplasms × Botulinum Toxins, Type A × Clear all
NCT02965976 2023-02-16

Botulinum Toxin Type A in Preventing Complications After Surgery in Patients With Esophageal Cancer

Roswell Park Cancer Institute

Phase 2 Completed
33 enrolled 17 charts
Gastrointestinal

Esophageal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡